Fig. 1 Concept of study and identification of DRL for cancer cell–based self-targeting therapies. Concept of study and identification of DRL for cancer.

Slides:

Advertisements

Similar presentations

Cytotoxicity of MSP samples to normal and cancer cell lines.

Advertisements

Basic design concept of human mimetic humanoid.

Three different types of transfer functions with a codomain of [0,1].

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Fig. 1 Movement percepts for all participants.

Fig. 4. Peanut-specific TH2A cells are specifically targeted during immunotherapy. Peanut-specific TH2A cells are specifically targeted during immunotherapy.

Cell viability tests. Cell viability tests. SEM images of (A) MC3T3-E1 cells and (B) MSCs on days 1, 3, and 5 of culture. (C) Survival rates of MC3T3-E1.

Fig. 2 Global production, use, and fate of polymer resins, synthetic fibers, and additives (1950 to 2015; in million metric tons). Global production, use,

Fig. 4. PVSRIPO infection of DCs is sublethal, is marginally productive, and induces sustained proinflammatory cytokine production. PVSRIPO infection of.

Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.

In vivo release of doxycycline hyclate from the GRS in a swine model

Fig. 1 AVPR1A is regulated by the AR coactivator VAV3 and AR-V7 and is increased in advanced human PC. AVPR1A is regulated by the AR coactivator VAV3 and.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Toxicity and management in CAR T-cell therapy

Fig. 5. In vivo characterization of adipogenesis by CT.

Fig. 3 Glucose- and structure-dependent insulin release.

Fig. 3 NK cells are enriched in ICB-sensitive tumors in mouse models and patients and are required for response. NK cells are enriched in ICB-sensitive.

MR1Ts recognized by the hpMR1+EC tetramer are more likely to be TRAV1-2−. MR1Ts recognized by the hpMR1+EC tetramer are more likely to be TRAV1-2−. PBMCs.

Fig. 1 Product lifetime distributions for the eight industrial use sectors plotted as log-normal probability distribution functions (PDF). Product lifetime.

Fig. 1 Cryo-EM structure of yeast Elp123 showing its active site.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Fig. 1. CAR4 and CAR8 cells demonstrate in vitro and in vivo antileukemic efficacy. CAR4 and CAR8 cells demonstrate in vitro and in vivo antileukemic efficacy.

Fig. 4 Rational therapeutic modulation of the tumor microenvironment sensitizes tumors to ICB. Rational therapeutic modulation of the tumor microenvironment.

Fig. 3 BMS blocks functional responses in primary immune cells driven by IL-23 and IL-12. BMS blocks functional responses in primary immune.

BMS blocks functional responses in primary immune cells driven by IFNα

In vitro cell-release experiments on a glass substrate.

Fig. 1 Caspase-8 and -9 are both activated during intrinsic and extrinsic apoptosis. Caspase-8 and -9 are both activated during intrinsic and extrinsic.

Fig. 6 WPS imaging of different chemical components in living cells.

Fig. 2 L. lactis–derived lactic acid antagonizes V

MR1Ts respond to microbially derived ligands loaded on hpMR1 tetramers

Fig. 5 Simultaneous absence of caspase-3 and -7 is required for significant decrease of caspase-8 and -9 activation in intrinsic apoptosis. Simultaneous.

AEGIS autonomous targeting process.

Fig. 3 ET dynamics on the control and treatment watersheds during the pretreatment and treatment periods. ET dynamics on the control and treatment watersheds.

Fig. 2 Extended local release of agonists of innate immunity prevents tumor recurrence and eliminates distal metastases. Extended local release of agonists.

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

Fig. 4. Paclitaxel promotes the expression of invasive isoforms of MENA in the primary breast cancer microenvironment. Paclitaxel promotes the expression.

Fig. 1 Cross-sectional images of He-implanted V/Cu/V samples.

Fig. 4 Evolution of fraction of sickled RBCs under hypoxia.

Single-cell analyses to tailor treatments

Representative CT and PET/CT images of three patients with NSCLCs

Fig. 3 Production of protein and Fe(II) at the end of growth correlated with increasing concentrations of ferrihydrite in the media that contained 0.2.

Fig. 1 Crohn’s disease association within the LRRK2 locus.

Fig. 3 Prophylactic or therapeutic use of DECON protects from herpes infections in vitro. Prophylactic or therapeutic use of DECON protects from herpes.

Fig. 1 Prophylactic, neutralization, and therapeutic efficacy of HPAC.

Fig. 2 Effect of CSF sTREM2– and CSF sTREM2–to–p-tau181 ratio on changes in cognition. Effect of CSF sTREM2– and CSF sTREM2–to–p-tau181 ratio on changes.

Fig. 2 Isopropanol-tolerant E. faecium resists disinfection.

Fig. 5 In vivo gene delivery by the T4-AAV nanoparticles.

Fig. 5 Comparison of the liquid products generated from photocatalytic CO2 reduction reactions (CO2RR) and CO reduction reactions (CORR) on two catalysts.

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Fig. 1 Location of the Jirzankal Cemetery.

Fig. 2 Increasing KLF17, CDH1, and LASS2 expression reduced malignant progression and promoted apoptosis of tumor cells. Increasing KLF17, CDH1, and LASS2.

Fig. 8. TIE2 inhibitor rebastinib eliminates the prometastatic effects of paclitaxel. TIE2 inhibitor rebastinib eliminates the prometastatic effects of.

Fig. 5. High burdens of AA signature mutations and predicted immunogenicity in Taiwan HCCs. High burdens of AA signature mutations and predicted immunogenicity.

Fig. 3 Effects of ASO and eGLP1-ASO conjugates on gene expression and protein levels in vitro in cell lines and primary mouse islet cells. Effects of ASO.

Fig. 2 BX795 is nontoxic to HCE cells at therapeutic concentration.

Fig. 5 In vivo autologous self-targeting efficacy of DR-KO tumor cells co-engineered with a secretable DRL and a suicide system. In vivo autologous self-targeting.

Fig. 7 BEL immune response.

Fig. 4 Behavior of resistance peak near density nm = 5.

Fig. 5 Cytosolic delivery of toxic proteins.

Fig. 4 Gallium increases P. aeruginosa sensitivity to peroxides.

Fig. 1 ETL kills 4T1 breast carcinoma cells more efficiently than ST under static conditions. ETL kills 4T1 breast carcinoma cells more efficiently than.

Fig. 2 Daily TNC pickups and drop-offs for an average Wednesday in fall 2016 (1). Daily TNC pickups and drop-offs for an average Wednesday in fall 2016.

Fig. 5. Paclitaxel promotes breast cancer cell dissemination and metastasis in a MENA-dependent manner. Paclitaxel promotes breast cancer cell dissemination.

Fig. 2. Cellular response to FolamiRs in vitro.

Fig. 4 Orthosteric ligand-binding pocket in CysLT1R.

Fig. 4 Rotavirus induces the type I IFN pathway and release of ATP by tumor cells. Rotavirus induces the type I IFN pathway and release of ATP by tumor.

Presentation transcript:

Fig. 1 Concept of study and identification of DRL for cancer cell–based self-targeting therapies. Concept of study and identification of DRL for cancer cell–based self-targeting therapies. (A) Allogeneic approach: Cancer cells resistant to receptor-targeted therapies can be used off-the-shelf for delivery of receptor ligands toward allogeneic cancers with ligand-sensitive phenotypes in the setting of primary treatment. Because they are co-engineered with a prodrug-activatable suicide system [herpes simplex virus thymidine kinase (HSV-TK)], therapeutic cancer cells can be eliminated after therapy using ganciclovir (GCV). (B) Autologous approach: Cancer cells harvested from patients during initial surgery and identified as sensitive to receptor-targeted therapies can be CRISPR-engineered to knock out the target receptors. Receptor knockout (KO) results in therapy resistance and allows engineering with receptor ligands and delivery toward autologous self-tumor sites in the setting of recurrence. (C) A panel of primary and metastatic cancer cell lines was treated with conditioned medium containing secretable variants of different receptor-targeted molecules, and viability was assessed 72 hours after treatment (n = 3 technical replicates). TSP, thrombospondin-1; Nb, nanobody. (D) Cancer cell lines were tested with varying concentrations of TRAIL to quantify TRAIL sensitivity (n = 3 technical replicates). TRAIL-sensitive (s) or -resistant (r), nodular (n) and invasive (i) glioblastoma (GBM), colon cancer (CC), T cell leukemia (TCL), metastatic breast cancer (BCm), and metastatic prostate cancer cells (PCm) were tested. All in vitro experiments were repeated at least twice. Means ± SD are shown. P values by unpaired t test. **P < 0.01, ***P < 0.001. Clemens Reinshagen et al., Sci Transl Med 2018;10:eaao3240 Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works